MUC1 and ovarian cancer: Up to 90% of breast tumors, approximately 70%–90% of pancreatic ductal adenocarcinomas and ovarian cancers (OvCas), 50%–80% of lung adenocarcinomas and colorectal cancer, and 30%–70% of prostate cancers reported to express abnormal MUC1 expression.7